Alexion Pharmaceuticals Inc. shares rose 1.4% to $101.57 in morning trade Friday, after the company announced several new executives will start June 5. The news follows a massive managerial shake-up at the biopharmaceutical company in late May, in which Alexion announced the departures of its chief commercial officer, chief financial officer — who started at the company in December — and two executive vice presidents. The company has faced a scandal over sales practices for its expensive blood disorder medication Soliris. Alexion named John Orloff, who previously served as executive vice president at Novelion Therapeutics Inc. , as its head of research and development, and named Anne-Marie Law, who previously served as chief human resources officer at Hyatt Hotels Corporation , as the new chief human resources officer. Alexion also named Indrani Lall Franchini, previously chief compliance officer at Hess Corporation , as its new chief compliance officer. Alexion shares have dropped 23.5% over the last three months, compared with with a 2% rise in the S&P 500 .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News